143results about How to "Avoid immune rejection" patented technology

The invention discloses humanized genetic recombinant human-like collagen produced by eukaryotic bacteria. The humanized genetic recombinant human-like collagen has amino acid with the total length of 474, and is formed by connecting two sections of completely-identical human III-type collagen sections in series; the end C is connected with six histidine residue groups serving as specificity affinity purification markers. The performance of the genetic recombination human-like collagen is superior to animal collagens and original nuclear engineering bacteria recombinant collagens; and with the specificity affinity purification markers, the high-purity product is easily acquired.

The invention relates to a medical dressing with bioactivity and a preparation method of the medical dressing and belongs to the technical field of biomedical engineering and material science. The medical dressing with the bioactivity is used for covering skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repair and is prepared as follows: one or more of embryonic stem cells, umbilical cord blood stem cells, amniotic fluid stem cells, peripheral blood stem cells and bone mesenchymal stem cells of humans or animals are cultured in vitro, stem cell growth factors secreted in the logarithmic growth phase are collected and mixed in proportion with one or more of I type collagen, III type collagen, chitosan, hyaluronic acid, chondroitin sulfate and sodium alginate, thin-layer sponge is taken as an inner layer, a porous high-polymer material film outer layer prepared from a mixture formed by one or more of PLA (polylactic acid), PGA (polyglycolic acid), PLGA (poly(lactic-co-glycolic acid)) and PCL (polycaprolactone) is attached, the product is frozen-dried and cut, and the medical dressing with the bioactivity is formed and used for treating skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repairing.

The invention relates to a method for preparing for organization project cell epimatrix, which adopts animal stromatin and desmocyte as raw material. It comprises: preparing for the culture liquid, extracting the stromatin, preparing for the cell-stromatin culture material, preparing for the cell epimatrix, dispelling the cell by freezing, and sterilization sanitizing packaging material and so on.

Adoptive immunotherapy using T cells genetically redirected via expression of chimeric antigen receptors (CARs) is a promising approach for cancer treatment. However, this immunotherapy is dependent in part on the optimal molecular design of the CAR, which involves an extracellular ligand-binding domain connected to an intracellular signaling domain by spacer and/or transmembrane sequences.

The invention discloses a tissue engineering double-layer skin and a preparation method thereof. The tissue engineering double-layer skin is characterized by being constructed by using fibroblast cells and epidermal cells as seed cells and an acellular amniotic membrane as a biological scaffold. The tissue engineering double-layer skin disclosed by the invention has the advantages of low cost, simple operation, wide sources and easy storage, and is a skin substitution having high transplantation efficiency. The invention also provides the preparation method of the tissue engineering double-layer skin.

The invention discloses a degradable medicine slow release function composite enteric stent. The degradable medicine slow release function composite enteric stent comprises an inner layer tubular stent and an outer layer medicine film, the inner layer tubular stent is a degradable tubular stent with a three-dimensional textile structure and has good flexibility and supporting performance, the textile structure is a weft-knitted structure or a braided structure, and yarns are mutually nested through a coil or are braided according to a certain braiding rule in order to form the tubular stent with stable structure and stable mechanical performances; and the outer layer medicine film is a fibroin protein solution medicine loaded coating, and the external surface of the textile structure is coated or laminated with the outer layer medicine film. The invention also discloses a making method of the enteric stent. The stent can support pathologic intestinal tracts, alleviate patients' intestinal obstruction and recovers patients' normal defecation; and the surface applied to the intestinal obstruction position is loaded with an antitumor medicine in order to realize a targeting therapy effect.

The invention belongs to the field of biotechnology, and particularly relates to a chimeric antigen receptor based on a human mesothelin antibody, a lentiviral expression vector and applications of the chimeric antigen receptor. The chimeric antigen receptor is composed of a human CD8a molecular signal peptide, a humanized mesothelin single-chain antibody, a human CD8a molecular flexible fragment,a human CD28 molecular transmembrane region and intracellular region, a human 41BB intracellular region, and a human CD3z intracellular region which are sequentially connected in series. The chimericantigen receptor prepared by the invention can target mesothelin and improve the therapeutic effect of CAR-T cells.

The present invention relates to a cervical intraepithelial neoplasia model and the method of establishing model, which is characterized in that the cervical intraepithelial neoplasia tissue is embedded in the immunodeficiency mice to establish cervical intraepithelial neoplasia model. The method of establishing model is characterized in that the cervical intraepithelial neoplasia tissue is respectively taken from the biopsy under the vaginoscope and the tissues which are confirmed by the department of pathology and is inoculated subcutaneously in the back of the mice; the immunodeficiency mice of the present invention can overcome the xenoislet immune rejection reaction and receive the transplantation of the human tumor tissues, the tissue model after the transplantation has significant and stable character, short observation period and greater clinical reference significance of the experimental results. The present invention can explore the mechanism of the carcinogenesis of cervical carcinoma by outcome of the pathological process of CIN I, CIN II and CIN III animal models. Furthermore, by observing the period of the outcome of the cervical intraepithelial neoplasia tissue of the animal model, the present invention provides the feasible clinical animal experimental model for reversing the malignant transformation of the CIN I and CIN II lesion tissues.

The invention provides a method for generating autologous retinal stem cells and autologous retinal cells by reversely differentiating human body cells. The method comprises the following steps of: culturing the human body cells in steps in a culture medium which contains different plant extracts and proteins, so that the human body cells are reversely differentiated to generate the autologous retinal stem cells and then continuously generate a plurality of autologous retinal cells. Tens of billions of a first generation of autologous retinal stem cells are generated within 2 to 3 weeks. The plant and protein-induced human autologous retinal stem cells have the same cell specific phenotype as human natural retinal stem cells and various cell differentiation abilities. The autologous retinal stem cells and the autologous retinal cells have good application prospect in the field of treating diseases, such as retinal pigment degeneration, and also have good potential application prospect in the fields of regenerative medicine and autologous tissue organ engineering. The autologous retinal stem cells and the autologous retinal cells have the possibility to be produced massively in an industrialization way.

The invention discloses a decellularized fiber ring matrix preparation method and belongs to the technical field of animal cells or tissues. The decellularized fiber ring matrix preparation method includes taking spinal fiber ring of a healthy adult pig, sufficiently rinsing the spinal fiber ring by sterile saline solution; placing the spinal fiber ring into Tris buffer solution of concentration 10mM and with 0.05-0.5% of EDTA (ethylene diamine tetraacetic acid) and 5-50KIU/ml of aprotinin and oscillating at the temperature of 4 DEG C; then placing the spinal fiber ring into the Tris buffer solution containing 1-5% of TritonX-100, oscillating at room temperature; placing the spinal fiber ring into Tris buffer solution containing 0.05-0.5mg/ml of deoxyribonuclease, 5-50microgram/ml of ribonuclease A, and oscillating; and finally, washing by sterile saline solution with oscillating, and storing in sterile PBS (phosphate buffer solution) at the temperature of 4 DEG C. The decellurlarized fiber ring matrix preparation method is simple in preparation process, thorough in decellurlarization and complete in reserved structure, similar in matrix content and mechanical performance as those of natural fibers, and is a good tissue engineering fiber ring support material.

The invention discloses yeast recombined human-source I-type collagen alpha1 chain protein, a synthesis method and an application thereof. The recombinant human-source I-type collagen alpha1 chain protein is composed of N-terminal affinity purification marker, human-source I-type collagen alpha1 chain mature peptide sequence and C-terminal affinity purification marker, and the double specific affinity purification markers are designed at two ends of the protein, so that purification of the recombinant protein is facilitated, and detection and full-length identification of the recombinant protein are facilitated. The synthesis method includes utilizing pichia pastoris idiomatic codon to optimize a collagen gene sequence and performing artificial whole-gene synthesis on a gene level; building a recombinant vector through PCR, enzyme digestion and connection, and integrating the recombinant vector into yeast chromosome to build a recombinant pichia pastoris engineered strain secreting andexpressing the recombined human-source I-type collagen alpha1 chain protein. The double specific affinity purification markers carried by the protein is supportive of two-step specific purification,and easiness in acquiring a high-purity product is realized.